News Bayer aims at J&J and Pfizer with new prostate cancer drug The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
